Novo Nordisk’s Akero Bid Centered On Addressing Cirrhotic MASH

 
• By Joseph Haas
  
breaking news
With its bid for Akero, Novo Nordisk is looking to cover the whole spectrum of MASH therapy (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business